Oxford Biomedica plc (OTCMKTS:OXBDF – Get Rating)’s stock price traded up 1.1% during trading on Monday . The company traded as high as $6.07 and last traded at $6.06. 1,110 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 4,423 shares. The stock had previously closed at $6.00.
A number of analysts have commented on OXBDF shares. Zacks Investment Research cut shares of Oxford Biomedica from a “hold” rating to a “sell” rating in a report on Wednesday, April 27th. HC Wainwright reiterated a “buy” rating on shares of Oxford Biomedica in a research note on Wednesday, April 20th.
The business’s fifty day moving average price is $7.62 and its two-hundred day moving average price is $11.73.
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes.
- Get a free copy of the StockNews.com research report on Oxford Biomedica (OXBDF)
- Short-Covering Begins In Big Lots
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Institutions Ring The Register On Toll Brothers Stock
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- It’s Time to Buy into Planet Fitness Stock
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.